Improved selectivity for high-performance liquid chromatographic determination of clonazepam in plasma of epileptic patients.
We report a high-performance liquid chromatography method for clonazepam determination in plasma. The use of a synthetic silica-based stationary phase markedly improved clonazepam resolution compared to standard reversed-phase columns. A liquid-liquid extraction was used, associated with reversed-phase chromatography, gradient elution and ultraviolet detection. Accuracy and precision were satisfactory at therapeutic concentrations. Selectivity was studied for benzodiazepines or other antiepileptic drugs, with particular attention to newly marketed drugs i.e., gabapentine and vigabatrin. No interfering substance was evidenced. Under the conditions described, it was possible to quantify clonazepam at nanogram level even when carbamazepine was present at therapeutic concentrations.
Le Guellec
C
C
Laboratory of Pharmacology and Toxicology, CHU Bretonneau, Tours, France.
Gaudet
M L
ML
Breteau
M
M
D000927:Anticonvulsants / Q000097:blood* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D002998:Clonazepam / Q000097:blood* / Q000627:therapeutic use; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet
D000927:Anticonvulsants; D002998:Clonazepam